Turku - Juvantia Pharma Ltd. presented positive results from a double blind, randomized, placebo controlled phase-2a study on its lead product candidate Fipa-mezole (JP-1730) in late June during the International Congress of Parkinson's Disease and Movement Disorders in Rome, Italy. The data gained from 16 patients demonstrate that Fipamezole reduced Levodopa-induced dyskinesias and prolonged Levodopa's duration of action in advanced Parkinson's disease patients, providing proof-of-concept for Fipa-mezole. “The outcome of this study supports the further clinical development of Fipamezole for treatment of motor complications in Parkinson's disease”, says CEO Juha-Matti Savola. “The completion of this trial has been the most significant milestone for our company,” he continues. Fipamezole acts on -2 adrenergic recep-tors, and it represents a potential new class of Parkinson's disease medications. Non-dopaminergic therapeutic concepts such as Fipamezole are considered among the most promising therapeutic approaches.